phase readout
saveNCT06813911: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)
view source ↗
comments(0)
5-min edit window · permanent after that